Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01J: MK-1084 in First-line KRAS G12C-mutated NSCLC
NCT07252739Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2025
- Primary completion
- Nov 2029
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, open-label trial of calderasib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Merck & Co. Primary endpoints: Dose Limiting Toxicity at 21 days, Adverse Events at 84 months and 2 more. Started Dec 2025; status: recruiting.
02
Drugs
calderasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07252739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07252739.